Investigator discretion due to lack of efficacy in three subjects enrolled

The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.

Inclusion Criteria:

• patients with vision-threatening autoimmune uveitis
• failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects

Exclusion Criteria:

• serious concomitant illness that could interfere with the subject's participation
• previous or current use of an alkylating agent
• use of CYP3A4 inhibitors during the trial
• TNF blocker use within the 8 weeks prior to enrollment

patients with refractory uveitis

Study was terminated prematurely due to inefficacy in the three initial patients enrolled. Endpoints were not analyzed as participants did not make it to the 6 month time frame before discontinuing the study.